<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758689</url>
  </required_header>
  <id_info>
    <org_study_id>REC/002-2021</org_study_id>
    <nct_id>NCT04758689</nct_id>
  </id_info>
  <brief_title>Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients</brief_title>
  <official_title>Laser Acupuncture in Rheumatoid Arthritis Geriatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying the effect of laser acupuncture on geriatric patients with rheumatoid arthritis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Actual">December 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>Baseline</time_frame>
    <description>interleukin 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>4 weeks</time_frame>
    <description>interleukin 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Malondialdehyde (MDA)</measure>
    <time_frame>Baseline</time_frame>
    <description>malondialdehyde</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Malondialdehyde (MDA)</measure>
    <time_frame>4 weeks</time_frame>
    <description>malondialdehyde</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adenosine Triphosphate (ATP)</measure>
    <time_frame>Baseline</time_frame>
    <description>adenosine triphosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adenosine Triphosphate (ATP)</measure>
    <time_frame>4 weeks</time_frame>
    <description>adenosine triphosphate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Baseline</time_frame>
    <description>C-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>4 weeks</time_frame>
    <description>C-reactive protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Arthritis Quality of Life (RAQoL)</measure>
    <time_frame>Baseline</time_frame>
    <description>rheumatoid arthritis quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Arthritis Quality of Life (RAQoL)</measure>
    <time_frame>4 weeks</time_frame>
    <description>rheumatoid arthritis quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>Baseline</time_frame>
    <description>health assessment questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>4 weeks</time_frame>
    <description>health assessment questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Laser acupuncture and aerobic exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerobic exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Laser, exercise, and methotrexate</intervention_name>
    <description>Laser therapy at acupuncture points, aerobic exercise, and methotrexate</description>
    <arm_group_label>Laser acupuncture and aerobic exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Exercise, and methotrexate</intervention_name>
    <description>Aerobic exercise, and methotrexate</description>
    <arm_group_label>Aerobic exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred from physician (immunologist) diagnosed with rheumatoid arthritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients having the disease overlapping with other connective tissue diseases, such as&#xD;
             systematic lupus erythromatosus and systematic sclerosis.&#xD;
&#xD;
          -  History of malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>A. Sedky</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>May 2, 2021</last_update_submitted>
  <last_update_submitted_qc>May 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>A. Sedky</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

